Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUC: Vacc-4x and Romidepsin in HIV-1
NCT02092116Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2014
- Primary completion
- Aug 2015
- Countries
- 1
- Sponsor
- Immunor
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Drugs
- Vacc-4xromidepsin
- Conditions
- human immunodeficiency virus type 1 infection (HIV-1)
01
Overview
Phase 2, open-label trial of Vacc-4x and romidepsin in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Immunor. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 3 weeks and Changes From Baseline in HIV-1 Reservoir at Day 175. Started Mar 2014; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Part A: Romidepsin
Romidepsin alone for safety and reactivation assessment
Part B: Vacc-4x + Romidepsin
Vacc-4x immunization followed by Romidepsin reactivation
03
Endpoints
Primary
Number of Participants With Adverse Events and Serious Adverse Events
Changes From Baseline in HIV-1 Reservoir
Secondary
Changes From Baseline in HIV-1 Reservoir
Number of Participants With Adverse Events and Serious Adverse Events
Level of HIV-1 Transcription
Beyond the preview
Go deeper on NCT02092116.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092116.